Table 5.

Multivariate regression using Fine-Gray subdistributional hazards model of calcific uremic arteriolopathy adverse events (safety analysis set)

Multivariate ModelHazard Ratio (95% CI)P Value
Treatment (cinacalcet versus placebo)0.25 (0.10 to 0.67)<0.01
Male sex (reference, female)0.33 (0.14 to 0.75)<0.01
Body mass index (per kg/m2)1.09 (1.05 to 1.13)<0.001
Diastolic BP (per 10 mmHg)1.50 (1.19 to 1.90)<0.001
History of dyslipidemia2.15 (0.90 to 5.15)0.09
History of parathyroidectomy5.79 (1.79 to 18.70)0.003
Baseline tobacco use (reference, never use)
 Current1.79 (0.54 to 5.89)0.34
 Former3.04 (1.19 to 7.74)0.02
  • Baseline variables were included using backward elimination. Heart failure and diabetes mellitus were removed during the backward elimination procedure at a significance level of 0.10. Additional baseline variables of age, vitamin K antagonist use, vitamin D sterol use, and peripheral vascular disease were evaluated but not included in the multivariate regression model using the backward elimination procedure because they did not meet the entry criteria, P<0.25 in a univariate model. 95% CI, 95% confidence interval.